

August 12, 2022

VIA ELECTRONIC PORTAL

Mr. Christopher J. Kirkpatrick
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

Re: FOIA Confidential Treatment Request

To Whom It May Concern:

Via electronic portal dated today, August 12, 2022, Chicago Mercantile Exchange Inc. ("CME" or "Exchange") submitted a supplemental product certification filing (Submission No. 22-287S) to the Commodity Futures Trading Commission ("CFTC" or "Commission") regarding the initial listing of the Bitcoin Euro Futures and Ether Euro Futures contracts. The supplemental filing includes an Appendix A for which the Exchange is submitting a detailed written justification setting forth grounds for this request for confidential treatment. The Confidential Information contains confidential and proprietary commercial information that could, if disclosed to the public, cause substantial harm to the competitive position of the submitter.

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), CME requests confidential treatment of the Confidential Information on the grounds that the Confidential Information contains confidential commercial information of the submitter (CME). Pursuant to Commission Regulation 145.9(d)(5), CME requests that confidential treatment be maintained for the Confidential Information until further notice from CME. We also request that the Commission notify the undersigned immediately after receiving any FOIA request for the Confidential Information or any other court order, subpoena or summons for same. Finally, we request that we be notified in the event the Commission intends to disclose the Confidential Information to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. CME does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for the Confidential Information.

Please contact the undersigned at (212) 299-2200 should you have any questions concerning this letter.

Sincerely,

/s/ Christopher Bowen
Managing Director and Chief Regulatory Counsel